Fate Therapeutics jumps in debut

|About: Fate Therapeutics, Inc. (FATE)|By:, SA News Editor

Fate Therapeutics (FATE +13%) opens at $6.56 and moves sharply higher.

The offering priced at the low-end of its expected range, notable because the company had already lowered the range to $6-8 from $14-16.

FATE's lead product is ProHema, a hematopoietic stem cell therapeutic derived from umbilical cord blood.